Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roy Fleischmann

Showing results (131-140 of 190) with videos related to

Pageof 19
Sort By:
Rheumatology (Oxford, England)|May 19, 2012
Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trialEdward C Keystone, Bernard Combe, Josef Smolen, et al.
The New England Journal of Medicine|August 10, 2012
Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritisRoy Fleischmann, Joel Kremer, John Cush, et al.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|December 21, 2013
Effect of golimumab on carotid atherosclerotic disease measures and cardiovascular events in inflammatory arthritidesMary Chester Wasko, Elizabeth C Hsia, Bruce Kirkham, et al.
Seminars in Arthritis and Rheumatism|June 5, 2013
Proceedings of the 2013 Rheumatology Winter Clinical SymposiaArthur Kavanaugh, Roy Fleischmann, Martin Jan Bergman, et al.
Seminars in Arthritis and Rheumatism|September 5, 2018
A pooled analysis of the safety of tofacitinib as monotherapy or in combination with background conventional synthetic disease-modifying antirheumatic drugs in a Phase 3 rheumatoid arthritis populationAlan J Kivitz, Stanley Cohen, Edward Keystone, et al.
Rheumatology and Therapy|February 1, 2023
Clinical Efficacy of Sarilumab Versus Upadacitinib Over 12 weeks: An Indirect Treatment ComparisonThomas Huizinga, Ernest Choy, Amy Praestgaard, et al.
The Journal of Rheumatology|November 17, 2017
Effect of Glucocorticoids on the Clinical and Radiographic Efficacy of Tofacitinib in Patients with Rheumatoid Arthritis: A Posthoc Analysis of Data from 6 Phase III StudiesChristina Charles-Schoeman, Désirée van der Heijde, Gerd R Burmester, et al.
Rheumatology and Therapy|November 11, 2018
Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 StudiesPeter Nash, Laura C Coates, Roy Fleischmann, et al.
Rheumatology and Therapy|December 8, 2021
Differential Changes in ACPA Fine Specificity and Gene Expression in a Randomized Trial of Abatacept and Adalimumab in Rheumatoid ArthritisOmar Jabado, Michael A Maldonado, Michael Schiff, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 19, 2016
Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor InhibitorsRoy Fleischmann, Janet van Adelsberg, Yong Lin, et al.
Pageof 19

Showing results (131-140 of 190) with videos related to

Sort By:
Pageof 19
Rheumatology (Oxford, England)|May 19, 2012
Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trialEdward C Keystone, Bernard Combe, Josef Smolen, et al.
The New England Journal of Medicine|August 10, 2012
Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritisRoy Fleischmann, Joel Kremer, John Cush, et al.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|December 21, 2013
Effect of golimumab on carotid atherosclerotic disease measures and cardiovascular events in inflammatory arthritidesMary Chester Wasko, Elizabeth C Hsia, Bruce Kirkham, et al.
Seminars in Arthritis and Rheumatism|June 5, 2013
Proceedings of the 2013 Rheumatology Winter Clinical SymposiaArthur Kavanaugh, Roy Fleischmann, Martin Jan Bergman, et al.
Seminars in Arthritis and Rheumatism|September 5, 2018
A pooled analysis of the safety of tofacitinib as monotherapy or in combination with background conventional synthetic disease-modifying antirheumatic drugs in a Phase 3 rheumatoid arthritis populationAlan J Kivitz, Stanley Cohen, Edward Keystone, et al.
Rheumatology and Therapy|February 1, 2023
Clinical Efficacy of Sarilumab Versus Upadacitinib Over 12 weeks: An Indirect Treatment ComparisonThomas Huizinga, Ernest Choy, Amy Praestgaard, et al.
The Journal of Rheumatology|November 17, 2017
Effect of Glucocorticoids on the Clinical and Radiographic Efficacy of Tofacitinib in Patients with Rheumatoid Arthritis: A Posthoc Analysis of Data from 6 Phase III StudiesChristina Charles-Schoeman, Désirée van der Heijde, Gerd R Burmester, et al.
Rheumatology and Therapy|November 11, 2018
Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 StudiesPeter Nash, Laura C Coates, Roy Fleischmann, et al.
Rheumatology and Therapy|December 8, 2021
Differential Changes in ACPA Fine Specificity and Gene Expression in a Randomized Trial of Abatacept and Adalimumab in Rheumatoid ArthritisOmar Jabado, Michael A Maldonado, Michael Schiff, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 19, 2016
Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor InhibitorsRoy Fleischmann, Janet van Adelsberg, Yong Lin, et al.
Pageof 19